NurseKim_ATL said:The mechanism is more central than most summaries suggest.
I read this differently. The confidence in this thread is running ahead of the evidence, and I would rather the uncertainty were stated than smoothed over because it is unsatisfying.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
One concrete data point for the thread. Numbers worth memorising for this class: Tmax one to three days for the weekly peptides, terminal half-life about a week for semaglutide and about five days for tirzepatide, steady state at four to five half-lives, subcutaneous bioavailability high enough that site choice is irrelevant.
JennaRN said:The confidence in this thread is running ahead of the evidence, and I would rather the uncertainty were stated than smoothed over because it is…
There is a second half to this that has not been said yet. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.
Ask again with the specifics and you will get a better answer than this one.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOne thing that is still open after pam_stl’s answer:
Which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working?
OP back with an update, since a thread like this is useless without one.
Update — tachyphylaxis to the gastric effect, persistence of the appetite effect. Two curves, and I had been watching the wrong one.